NCT01833728 is a NA clinical trial of nefopam-propacetamol combination in Renal Tumor, sponsored by Yonsei University.

Who is sponsoring NCT01833728?

NCT01833728 is sponsored by Yonsei University.

What drugs are being tested in NCT01833728?

Interventions in NCT01833728: nefopam-propacetamol combination, propacetamol alone.

What condition does NCT01833728 study?

NCT01833728 studies Renal Tumor.

Is NCT01833728 still recruiting?

NCT01833728 is currently completed. Last updated 17 February 2014.

Last reviewed 2014-02-17 · How we verify

NCT01833728

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy

Completed NA Last updated 17 February 2014

What this trial tests

NA trial testing nefopam-propacetamol combination in Renal Tumor in 16 participants. Completed in 1 January 2014.

Timeline

1 April 2013

Primary endpoint
1 January 2014

1 January 2014

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	1 April 2013
Primary completion	1 January 2014
Estimated completion	1 January 2014
Sites	1 location across South Korea

Drugs / interventions tested

nefopam-propacetamol combination — full drug profile →
propacetamol alone — full drug profile →

Conditions studied

Renal Tumor — all drugs for Renal Tumor →

Sponsor

Yonsei University

Who can join

Adults 20 to 65, any sex, with Renal Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Quality of Recovery
Time frame: at 24 hours postoperative
Quality of recovery questionnaire score at 24 hours after surgery

Sponsor's own description

The multimodal analgesia for postoperative pain aims for optimal analgesia through additive or synergic drug effects. The multimodal analgesia results in the use of smaller doses of opioids and lowering opioid-related side effects. Non-opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), propacetamol (prodrug of acetaminophen), nefopam are often given along with opioids as part of multimodal analgesia after major surgery. NSAIDS, commonly used non-opioid analgesics, have gastro-intestinal, renal, and cardiac side effects. In contrast, propacetamol or nefopam, two drugs with central analgesic effects, can be safely used as analgesic adjuvants with opioid after nephrectomy, because these drugs do not alter renal function or cause hemorrhagic complications. Recent study demonstrated that the antinociceptive properties of paracetamol (intravenous acetaminophen) associated with the analgesic effectiveness of nefopam could explain the observed synergy of the combination. The aim of this randomized, double-blinded study is to compare the opioid-sparing effect and analgesic efficacy, as well as quality of recovery, of nefopam-propacetamol combination and propacetamol in patients undergoing laparoscopic nephrectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Renal Tumor

Currently open trials in the same condition.

NCT06076538 — PET/MR for Characterization of Renal Masses (RMs) · recruiting
NCT05696444 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) · NA · active not recruiting
NCT03810651 — Pencil Beam Scanning in Patients With Renal Tumors · EARLY_PHASE1 · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01833728 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 17 February 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01833728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing